FLAURA2 Study: Mode Exploration of First-Line Treatment for Advanced NSCLC With <i>EGFR</i> Mutation

WANG Li-jie

doi:10.12019/j.issn.1671-5144.202404040

WANG Li-jie. FLAURA2 Study: Mode Exploration of First-Line Treatment for Advanced NSCLC With EGFR Mutation[J]. Journal of Evidence-Based Medicine, 2024, 24(3): 145-149. DOI: 10.12019/j.issn.1671-5144.202404040

Citation:

WANG Li-jie. FLAURA2 Study: Mode Exploration of First-Line Treatment for Advanced NSCLC With EGFR Mutation[J]. Journal of Evidence-Based Medicine, 2024, 24(3): 145-149. DOI: 10.12019/j.issn.1671-5144.202404040

Citation:

WANG Li-jie. FLAURA2 Study: Mode Exploration of First-Line Treatment for Advanced NSCLC With EGFR Mutation[J]. Journal of Evidence-Based Medicine, 2024, 24(3): 145-149. DOI: 10.12019/j.issn.1671-5144.202404040

FLAURA2 Study: Mode Exploration of First-Line Treatment for Advanced NSCLC With EGFR Mutation

WANG Li-jie

Graphical Abstract

Abstract

FullText(HTML)

References (26)

FLAURA2 Study: Mode Exploration of First-Line Treatment for Advanced NSCLC With EGFR Mutation

Catalog

Export File

Citation

Format

Content